Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection

European Journal of Medical Research

A Di Biagio¹  C Viscoli¹  G Icardi²  G Secondo¹  B Bruzzone²  C Bernardini¹  R Rosso¹ 

[1] Department of Infectious Diseases, University of Genoa, San Martino Hospital, Genoa, Italy;Department of Health Sciences, University of Genoa, San Martino Hospital, Genoa, Italy

关键词: etravirine;    darunavir;    adherence;    multidrug resistance;    vertically acquired HIV-1 infection;   

Others  :  1093901
DOI  :  10.1186/2047-783X-14-3-136

 received in 2009-01-30, accepted in 2009-02-03,  发布年份 2009

【 摘 要 】

Multiclass-drug resistance, often caused by poor treatment compliance, is a challenging problem in all categories of HIV-infected patients. Selective pressure is higher in youth for both biological and behavioral reasons. We report the case of a 15-year-old Caucasian male, with vertically acquired HIV-1 infection, who failed several lines of antiretroviral therapy and was successfully treated with darunavir/ritonavir and etravirine.

【 授权许可】

   
2009 I. Holzapfel Publishers

【 参考文献 】

• [1]Chen TK, Aldrovandi GM: Review of HIV Antiretroviral Drug Resistance. Pediatr Infect Dis J 2008, 27(8):749-752.
• [2]Green H, Gibb DM, Walker AS, Pillay D, Butler K, Candeias F, Castelli-Gattinara G, Compagnucci A, Della Negra M, de Rossi A, Feiterna-Sperling C, Giaquinto C, Harper L, Levy J, Saidi Y, Wintergerst U: Paediatric European Network for the Treatment of AIDS (PENTA). Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS 2007, 21(8):947-955.
• [3]Katlama C, Esposito R, Gatell JM, Goffard JC, Grinsztejn B, Pozniak A, Rockstroh J, Stoehr A, Vetter N, Yeni P, Parys W, Vangeneugden T, the POWER 1 study group: Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007, 21(4):395-402.
• [4]Poveda E, de Mendoza C, Martin-Carbonero L, Corral A, Briz V, González-Lahoz J, Soriano V: Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother 2007, 60(4):885-888.
• [5]Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, Pialoux G, Wilkin T, Peeters M, Vingerhoets J, de Smedt G, Leopold L, Trefiglio R, Woodfall B, DUET-1 study group: Efficacy and safety of TMC-125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled-trial. Lancet 2007, 370(9581):29-38.
• [6]Vingerhoets J, Peeters M, Azjin H, Tambuyzer L, Hoogstoel A, Nijs S, de Bethune M, Picchio G: An update of the list of NNRTI mutations associated with decreased virological response to etravirine: multivariate analysis on the pooled DUET-1 and DUET-2 clinical trial data [abstract 24]. Antivir Ther 2008, 13(Suppl 3):A26.
• [7]Boffito M, Winston A, Jackson A, Fletcher C, Pozniak A, Nelson M, Moyle G, Tolowinska I, Hoetelmans R, Miralles D, Gazzard B: Pharmacokinetics and antiretroviral response to Darunavir/ritonavir and Etravirine combination in patients with high-level viral resistance. AIDS 2007, 21(11):1449-1455.
• [8]Poveda E: New resistance score for tipranavir. AIDS Rev 2008, 10(2):127.
• [9]FDA - Intelence Prescribing Information 2008, 7-8. Available at: http://www.fda.gov/cder/foi/label/2008/022187lbl.pdf webcite. Accessed 25 October 2008
• [10]Van Dyke RB, Lee S, Johnson GM, Wiznia A, Mohan K, Stanley K, Morse EV, Krogstad PA, Nachman S, Pediatric AIDS Clinical Trials Group Adherence Subcommittee Pediatric AIDS Clinical Trials Group 377 Study Team: Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics 2002, 109(4):e61.